SCHEMBL13409663

SCHEMBL13409663

CCO[C@@H](C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318330 1.00
SCHEMBL3414553 1.00
SCHEMBL7730742 0.85 LMNA (0.60)
SCHEMBL15829075 0.80 LMNA (0.47)
SCHEMBL7647685 0.78 LMNA (0.45)
SCHEMBL31633561 0.76 LMNA (0.50)
SCHEMBL28639339 0.76 LMNA (0.50)
Ether SCHEMBL9720166 0.76 LMNA (0.50)
SCHEMBL19565562 0.76 LMNA (0.43)
SCHEMBL18469734 0.76 LMNA (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 US disclosed
US-20230203083-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-06-29 US disclosed
US-20130060013-A1 Compounds useful for treating neurodegenerative disorders SATORI PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-7705146-B2 Hepatitis C inhibitor peptide analogs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-27 US disclosed
US-20070110772-A1 VACCINES FOR BLOCKING TRANSMISSION OF PLASMODIUM VIVAX THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) 2007-05-17 US disclosed